News

Ruben Mesa, MD, director at Mays Cancer Center at UT Health San Antonio and MD Anderson Cancer Center, discusses myeloproliferative neoplasms and other rare cancers.

Plans for a clinical phase 2a trial to test a combination of tesofensine and metoprolol (Tesomet) for the treatment of hypothalamic obesity in both the United States and Europe are underway.

Two single-patient, Compassionate Use trials for RT001 have been initiated for late onset Tay Sachs (LOTS) disease and familial encephalopathy with neuroserpin inclusion bodies (FEIN or neuroserpinosis).

Barton-Maxell details the importance of caring for stage A heart failure patients in the primary care setting.

Researchers aimed to determine how prophylactic, topical NSAIDs affected the development of CME, specifically ketorolac tromethamine 0.4% and nepafenac 0.1%.

New research appears to show a causal link between HCV infection and dysbiosis of the gut microbiota.

Children with autism are nearly twice as likely to have any allergic condition than those without autism, researchers found.

The risks of vitamin E treatment seemed to outweigh the benefits in this particular case.

The FDA has approved venetoclax for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.

Positive data regarding phase 1/2 study for lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase (GO) for the treatment of primary hyperoxaluria type 1 (PH1), yielded positive results.

Brown spoke about the overall efforts to see patients in a timely manner, ensuring that timeliness and quality go hand-in-hand.

Planned analyses of phase 3 trial of gilteritinib as a maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations in acute myeloid leukemia (AML).

Depression in men–but not women–reduces the chances of pregnancy for infertile couples, a new study suggests.

A team of researchers in California found a way to short-circuit the protein that would otherwise allow HIV to wake from dormancy.

Between 60-80% of pediatric asthma exacerbations are triggered by respiratory pathogens. For most children, the common cold is the culprit.

The rare condition affects 30,000-40,000 US patients annually. Rituximab becomes its first indicated biologic treatment.

This is the first approved treatment option in over 60 years for patients with the disease.

The CDC reported that suicide rates have increased by at least 30% in half of all US states.

The guidelines included indications and contraindications, evidence supporting its use, and the use of nonparenteral forms of ketamine.

Updated research regarding the ANDROMEDA study indicates the efficacy of subcutaneous daratumumab (DARA SC) and cyclophosphamide, bortezomib, and dexamethasone (CyBorD) as a combination therapy in newly diagnosed light chain (AL) amyloidosis patients.

Brown discussed the overall importance of communication—between not just providers, but patients as well—in making sure the emergency department runs efficiently.

The FDA has granted Orphan Drug Designation (ODD) to is product, brincidofovir, for the treatment of smallpox, a serious, and often deadly infectious disease.

One-fifth of patients with TD recently surveyed reported they had no clinical support.

New drugs are celebrated for the lives they can improve, but it’s a long and arduous journey for those developing them and most treatments don’t make it to FDA approval.

Only 6% of respondents said they received any type of financial education during residency, while 79% felt strongly that it should be included in residency education.

The FDA grants Orphan Drug Designation to Ascendis Pharma’s long-acting prodrug of parathyroid hormone in development for the treatment of hypoparathyroidism.

Study suggests a link between Lynch syndrome (LS) and more cancer types than previously thought.

The first patient has been dosed in the phase 2 expansion portion of its monotherapy trial of eFT508 for the treatment of relapsed, refractory non-germinal center B cell (non-GCB) diffuse large B cell lymphoma (DLBCL).

Brown spoke about the process changes the hospital has made to improve the workflow of the emergency department.

The prevalence of HDP and neurodevelopmental disorders are associated with increased risks up to 70%, according to the systematic review and meta-analysis.